Estrogen replacement therapy: effects of starting age on final height of girls with chronic kidney disease and short stature

We investigated the age of starting Estrogen replacement therapy as a key parameter for reaching near normal Final Height (FH) in Chronic Kidney Disease (CKD) girls with growth retardation. This open label, quasi-experimental designed and matched controlled clinical trial was performed on CKD girls...

Full description

Saved in:
Bibliographic Details
Published in:BMC pediatrics 2022-06, Vol.22 (1), p.355-355, Article 355
Main Authors: Amirkashani, Davoud, Rohani, Farzaneh, Khodadost, Mahmoud, Hoseini, Rozita, Alidoost, Hamidreza, Madani, Sedigheh
Format: Article
Language:English
Subjects:
Acidosis
Adolescent
Age
Anemia
Body Height
Bone density
Children & youth
Chronic kidney disease
Clinical trials
Creatinine
Delayed puberty
Dwarfism - drug therapy
Electrolytes
Estrogen Replacement Therapy
Estrogens
Female
GH treatment
Girls
Growth disorders
Growth Hormone - pharmacology
Growth Hormone - therapeutic use
Growth hormones
Growth retardation
Human Growth Hormone - therapeutic use
Humans
Kidney diseases
Laboratories
Metabolism
Pediatrics
Peritoneal dialysis
Physical growth
Puberty
Renal Insufficiency, Chronic - drug therapy
Velocity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We investigated the age of starting Estrogen replacement therapy as a key parameter for reaching near normal Final Height (FH) in Chronic Kidney Disease (CKD) girls with growth retardation. This open label, quasi-experimental designed and matched controlled clinical trial was performed on CKD girls with short stature and later onset of puberty or delayed puberty according to clinical and laboratory investigations. Participants of group 1 and 2 had been treated with Growth Hormone (GH), and Ethinyl Estradiol (EE). EE was administered from 11 and 13 yrs. old in groups 1 and 2 respectively. Group 3 was selected from patients that did not accept to start GH or EE till 15 years old. The effect of the age of starting EE on FH, GH therapy outcomes, bone density, and calcium profile were evaluated. Overall, 16, 22, and 21 patients were analyzed in groups 1, 2, and 3 respectively. Mean Mid-Parental Height (MPH) had no significant difference between the 3 groups. GH therapy significantly enhanced mean FH in groups 1 and 2 in comparison with group 3 (β = - 4.29, p 
ISSN:1471-2431
1471-2431
DOI:10.1186/s12887-022-03406-y